Form D · Biotechnology
Kestrel Therapeutics Inc.
Boston, MA · CIK 0001853373
Offering snapshot reported Aug 12, 2025 · SEC filing
- Reported sold
- $5M Offering amount: $10M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Jul 28, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 12, 2025 | Initial | $5,000,000 | No comparison | 6 | SEC filing |
| Feb 21, 2025 | Initial | $8,000,000 | No comparison | 7 | SEC filing |
| Jan 11, 2022 | Initial | $7,500,000 | No comparison | 6 | SEC filing |
| Mar 25, 2021 | Initial | $228,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-554348
Source: Form D, filed Aug 12, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Frank G. Haluska | Director, Executive |
| Omar Khalil | Director |
| Denis Patrick | Director |
| Andrew Phillips | Director |
| Nicholas Saccomano | Director |
| Barbara Sosnowski | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Attn: Pagliuca Harvard Life Lab 127 Western Ave.
Boston, MA, 02134
Boston, MA, 02134